Viva Biotech contributed to a round that will help Regenacy Pharmaceuticals push its diabetic peripheral neuropathy candidate into phase 2 trials.

Regenacy Pharmaceuticals, a US-based developer of diabetic neuropathy treatments, completed a $30m series A round yesterday that included drug discovery technology and services provider Viva Biotech Holdings. Investment firm Cobro Ventures and venture capital firm Taiwania Capital Management co-led the round, which also featured Yonjin Venture, a subsidiary of financial holding company Yonjin Group, as…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.